Follow our Journeys
Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.
Associates Class of 2022 announced
The DAN Associate Program brings together some of the University’s brightest minds from graduate schools across Duke University — including the Duke University School of Medicine, Duke University - The Fuqua School of Business, Duke…
Sparta Biomedical spotlighted by World Economic Forum
Sparta Biomedical was recently spotlighted by the World Economic Forum on their Instagram. Read more to see the video and learn more about Sparta Biomedical.
Associate Spotlight: Daniel Luo, Ph.D.
A cancer biologist by training, Daniel joined our team three years ago and has since worked on countless diligence efforts, many of which eventually became our successful portfolio companies.
Duke University researchers have developed a gel-based cartilage substitute
Implants made of the material are currently being developed by Duke Capital Partners portfolio company Sparta Biomedical and tested in sheep. Researchers are gearing up to begin clinical trials in humans next year.
Duke Capital Partners portfolio company, xilis, has closed a $19M+ extension to its Series A financing
xilis is a pioneering biotech company developing its MicroOrganoSphereTM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development.
InnAVasc Medical, Inc., a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates.
InnAVasc, a Duke Capital Partners portfolio company, has been acquired by W. L. Gore & Associates. Gore will add InnAVasc's dialysis graft tech to its medical advanced materials unit.